NCT02461888 2025-12-17
MUKEight
University of Leeds
Phase 2 Completed
Clinical Trials
6 trialsNCT06050512 2024-11-19
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02499081 2021-06-11
UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment
University of Arkansas
Phase 2 Completed
NCT03492138 2020-05-29
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT01887587 2020-01-22
Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia
Medical College of Wisconsin
Phase 1 Terminated
NCT02578121 2017-01-23
UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination
University of Arkansas
Phase 2 Withdrawn